Enovis Corporation $ENOV Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its stake in shares of Enovis Corporation (NYSE:ENOV) by 18.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,171 shares of the company’s stock after selling 21,327 shares during the quarter. Thrivent Financial for Lutherans owned 0.17% of Enovis worth $2,562,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ENOV. AQR Capital Management LLC lifted its stake in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after acquiring an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its stake in shares of Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after acquiring an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi lifted its stake in shares of Enovis by 24,405.0% in the second quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after acquiring an additional 9,762 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 0.1%

NYSE:ENOV opened at $24.16 on Monday. The firm has a market capitalization of $1.39 billion, a PE ratio of -1.22 and a beta of 1.41. The stock has a 50 day moving average of $24.01 and a 200-day moving average of $25.28. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $36.82. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same period in the prior year, the firm posted $0.81 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts predict that Enovis Corporation will post 3.65 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ENOV. William Blair began coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Evercore reissued an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Enovis in a report on Friday. Finally, Wells Fargo & Company lowered their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.50.

Insider Transactions at Enovis

In other news, insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have acquired 5,000 shares of company stock worth $121,983. 2.90% of the stock is owned by insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.